Novorex key facts
as of Oct 2026- Developer of a biotechnology platform designed to accelerate drug discovery for challenging biological targets.
- Novorex is valued at approximately $40.6M as of Oct 2026 (last reported valuation).
- It has raised $33.2M; the latest was Later Stage VC ($14.0M) in Apr 2026.
- Notable investors include Tech Incubator Program for Startup, SBI Investment, KB Investment, Korea Development Bank, Hana Ventures — 17 tracked in total.
- Status: Privately Held (backing).
Novorex's last reported valuation, Apr 2026. Nothing priced has surfaced since.
- ·The complete investor list: 17 names
- ·Watch Novorex: the Monday email on marks, rounds and moves
Novorex funding rounds
No funding rounds for Novorex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Novorex
17+Novorex valuation
Novorex's last reported valuation was $40.6 million in Apr 2026. No priced round, secondary trade or fund mark has surfaced since.
Novorex investors
17 investors are on record for Novorex, including Tech Incubator Program for Startup, SBI Investment, KB Investment and Korea Development Bank.
About Novorex
Developer of a biotechnology platform designed to accelerate drug discovery for challenging biological targets. The company offers AI (artificial intelligence)-driven molecular prediction, fragment-based drug design, and biophysical validation, enabling pharmaceutical and biotechnology researchers to identify and optimize small molecule therapeutics for previously inaccessible targets.
- Sector
- Healthcare
- HQ
- Seongnam-si, South Korea
- Founded
- 2020
- Employees
- 28
- Website
- novorex.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.